Latest development of thrombolytic therapy for patients with acute ST-elevation myocardial infarction

Percutaneous coronary intervention (PCI) has become the preferred treatment for patients with acute ST-elevation myocardial infarction (STEMI). However, emergency PCI still could not be popularized or timely performed because of the limitation of talents, technology and equipments. Thrombolytic therapy improves the clinical efficacy of patients with acute ST-elevation myocardial infarction, which has become an indispensable means of primary reperfusion therapy. The earlier the thrombolytic therapy is performed, the greater the benefits are for the patients. It is of great benefit to choose the appropriate reperfusion strategy for patients with acute ST-segment elevation myocardial infarction under specific conditions. We will summarize the advantages and disadvantages of various thrombolytic drugs in this paper for the most rational choice of the fibrinolytic strategy and thrombolytic drugs.